Homoarginine concentrations correlate with early depressive symptoms and the reduction in physical functioning within

Andreas Baranyi1, Andreas Meinitzer2, Dirk von Lewinski3

  • 1Department of Psychiatry, Psychosomatics and Psychotherapeutic Medicine, Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, 8036, Graz, Austria. an.baranyi@medunigraz.at.

Scientific Reports
|January 9, 2025
PubMed

Insights

Low levels of the amino acid homoarginine (hArg) after acute myocardial infarction (AMI) are linked to early depressive symptoms like fatigue and poor concentration. Plasma hArg levels normalized after six months but were lower in females post-AMI.

Area of Science:

  • Cardiology
  • Biochemistry
  • Psychiatry

Background:

  • Early depressive symptoms after acute myocardial infarction (AMI) manifest as performance deficits.
  • Homoarginine (hArg), a non-proteinogenic amino acid, influences nitric oxide (NO) availability, impacting physiological performance.
  • Low plasma hArg levels post-AMI may contribute to performance-related depressive symptoms.

Purpose of the Study:

  • To track plasma hArg concentrations in AMI patients immediately, on day 4, and at 6 months post-event.
  • To investigate the association between hArg levels and early depressive symptoms following AMI.

Main Methods:

  • Longitudinal study design.
  • Measurement of plasma hArg concentrations at multiple time points after AMI.
  • Assessment of depressive symptoms using HAMD-17 and BDI-II scales, focusing on performance-related aspects.

Main Results:

  • Plasma hArg levels decreased by day 4 post-AMI, independent of patient demographics or AMI type.
  • hArg concentrations returned to baseline levels by 6 months.
  • Females exhibited lower hArg levels than males early after AMI.
  • Low hArg concentrations correlated with higher depression scores and performance-related symptoms (fatigue, poor concentration, reduced physical functioning) within days of AMI.

Conclusions:

  • Plasma hArg levels show a transient decrease after AMI, particularly in females.
  • Low hArg concentrations are associated with early performance-related depressive symptoms post-AMI.
  • hArg may play a role in the pathophysiology of early post-AMI depression.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
56
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
96
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381